Tolebrutinib, an investigative inhibitor of Bruton’s tyrosine kinase (BTK) being developed by Sanofi to treat all forms of multiple sclerosis (MS), shows the potential to be more potent than other BTK inhibitors also in advanced clinical trials, scientists reported. The findings, based on preclinical data, were shared at the Americas…
News
Using a two-step machine learning strategy, researchers have developed an algorithm to predict the risk of multiple sclerosis (MS) relapse based on data gleaned from electronic health records. “The two-step machine learning model predicts a patient’s future one-year MS relapse risk with clinically actionable accuracy, comparable to other clinical…
Hormonal changes over time — and especially those around menopause — are often associated with disability worsening in multiple sclerosis (MS) patients, which suggests that sex-specific hormone therapies may be useful in MS treatment. Burcu Zeydan, MD, assistant professor of neurology and radiology at Mayo Clinic, provided an overview…
The experimental medication ublituximab significantly reduces the number of new brain lesions with severe nerve cell degeneration in people with relapsing multiple sclerosis (MS) as compared with Aubagio (teriflunomide), according to new data from the Phase 3 ULTIMATE clinical trials. The findings showed that ublituximab induces a rapid…
A higher burden of lesions in the brain’s cortex is associated with a greater likelihood of disability worsening in multiple sclerosis (MS) and transition to secondary progressive MS (SPMS), researchers report. These results suggest that “monitoring cortical lesion volume … could be useful when stratifying risk of disability…
From celebrating artists’ works to sharing stories that bring to life the experience of multiple sclerosis (MS), Multiple Sclerosis Awareness Month is designed to call attention to this neurodegenerative disorder and the nearly 1 million U.S. residents it’s thought to affect. MS can cause a host of physical…
A faster rate of atrophy in the spinal cord of people in earlier stages of multiple sclerosis (MS) is likely to indicate “silent progression” — worsening disability in the absence of relapses — and a swifter conversion to secondary progressive MS (SPMS), new data show. Antje Bischof, MD, with…
People with multiple sclerosis (MS) who are treated with Mavenclad (cladribine) are less likely to experience a disease relapse than those who are treated with Gilenya (fingolimod), Tecfidera (dimethyl fumarate), or Aubagio (teriflunomide), according to an analysis of real-world data. The findings were presented at the Americas Committee…
Iron rim lesions, or specific regions of chronic inflammation seen on MRI scans of the brain, are associated with greater disability and poorer outcomes in multiple sclerosis (MS), a study indicates. These findings “could support the use of iron rim lesions as an imaging biomarker for disease severity and…
Researchers developed a new mouse model that more closely captures a specific type of inflammation characteristic of progressive multiple sclerosis (MS) — and found, in experiments, that treatment with an oral medication called evobrutinib can lessen disease activity. This new mouse model may help scientists in MS to better study…
Undergoing a stem cell transplant, a procedure that aims to “reset” a person’s immune system, can reduce relapse rates and ease disability in people with multiple sclerosis (MS), new data show. The findings suggest that such a transplant — fully, autologous hematopoietic stem cell transplantation or aHSCT — is…
A matrix protein called fibulin-2, which is increased in multiple sclerosis (MS) lesions, blocks the activity of oligodendrocytes, the cells responsible for making myelin. Blocking this protein may be a promising approach to restore myelin in people with the neurodegenerative disease, a study in mice showed. The data was…
Paramagnetic rim lesions, a specific form of inflammatory damage to the brain, are rarely found in people with disorders other than multiple sclerosis (MS), according to a study in adults with suspected MS. Its findings suggest that looking at PRLs could be useful for diagnosing the disease. Brain Renner,…
Machine learning — using computer algorithms — can be used to identify people with primary progressive multiple sclerosis (PPMS) who are more likely to respond to treatment, a new study shows. The ability to predict treatment response could allow clinical trials to be designed more efficiently, researchers said. Jean-Pierre…
Synaptogenix announced plans to advance bryostatin-1, its lead candidate, into clinical trials for multiple sclerosis (MS), marking the third neurological disease the small molecule therapy is being developed to potentially treat. “Multiple sclerosis joins Alzheimer’s disease (“AD”) and Fragile X syndrome as our third indication with potential clinical…
Levels of a protein called neurofilament light chain (NfL) in the blood can be used to predict the risk of future disease activity in people with multiple sclerosis (MS), according to a new study. The results also suggest that changes in NfL levels could be used to deduce the extent…
Multiple sclerosis (MS) patients who experience reductions in spasticity after a four-week course of inpatient rehabilitation can sustain those improvements in the long term using an app-based self-training program, according to data from a clinical trial. The app also led to better adherence to the self-training program than…
There has been a marked increase in the amount of research done regarding women’s health in multiple sclerosis (MS) over the last decade or two, but there remain substantial gaps in scientific knowledge, especially for topics outside of pregnancy, according to a scoping review. “Future studies are needed that…
Multiple sclerosis (MS) treatments belonging to the class of sphingosine 1-phosphate (S1P) receptor modulators — such as Mayzent (siponimod) and Gilenya (fingolimod) — may be associated with a greater likelihood of skin cancer, results from a real-world study suggest. The association was the greatest for a form of…
The psychological distress of a parent whose child is found to have multiple sclerosis (MS) may directly impact the quality of life of the child. That’s according to a new study that revealed a worse health-related quality of life (HRQoL) in MS children after their diagnosis. These findings support…
Myelin is required for certain inhibitory neurons — which help to suppress abnormal activity in the brain — to work as they should, according to a study in mouse models. Loss of myelin on these neurons results in excessive electric activity in other nerve cells, likely disrupting the brain’s ability…
An increased production of CD25 – an immune receptor that regulates T-cell proliferation and activation – is the most noticeable blood cell immune alteration in people with multiple sclerosis (MS) compared with their unaffected identical twins, a study discovered. The increased CD25 levels, which correlated with disease severity, were…
A researcher at the University of Adelaide, in Australia, has received an AU$390,000 grant (about $280,000) to investigate how inflammatory T-cells reach the blood and brain of people with multiple sclerosis (MS). The 3-year fellowship grant was awarded to Iain Comerford, PhD, for his project, titled “Stopping T cells…
Lower-than-normal volumes of certain brain regions at disease onset — indicating shrinkage, or atrophy, in those regions — are significantly associated with current and future fatigue severity in people with multiple sclerosis (MS), a study in Germany shows. Some of these regions also were found to be central brain…
A neurology professor at the University of Pennsylvania (UPenn) has received the 2021 Barancik Prize for Innovation in MS Research for his work in understanding how the immune system causes multiple sclerosis (MS). The international $100,000 prize, administered by the National MS Society, was awarded to Amit…
The MS Society of the U.K. intends to raise over £1.1 million (about $1.5 million) to support nine multiple sclerosis (MS) research projects, marking the return of the grants program it put on hold due to the COVID-19 pandemic. Funding will support research in the…
Therapeutics designed to produce new oligodendrocytes — the cells responsible for the protective myelin sheath that is damaged in multiple sclerosis (MS) — might be the most effective approach for disorders such as MS, according to a study conducted in a fish model. That’s because oligodendrocytes that survive being…
The addition of neurodynamic therapy — a type of manual therapy targeting the nerves — to a standard treatment regimen using several different approaches reduced pain sensitivity and improved dexterity in people with multiple sclerosis (MS), according to data from a clinical trial. “To the best of our…
VISIONARY-MS, a Phase 2 clinical trial evaluating the safety and effectiveness of CNM-Au8 in people with relapsing multiple sclerosis (MS) with disease-related visual impairment, will conclude early due to COVID-19 pandemic-related challenges. The release of trial data is expected in the second half of this year, according to…
The label of Copaxone (glatiramer acetate) — an approved therapy for relapsing forms of multiple sclerosis (MS) — has been updated in Europe to no longer contain a warning against its use during breastfeeding. The label update follows a review by European Union health authorities of non-clinical and clinical evidence submitted…